Posted by Michael Wonder on 05 Oct 2018
MHRA consults on new regulatory framework for ‘no-deal’ scenario
5 October 2018 - The Medicines and Healthcare products Regulatory Agency has launched a consultation seeking views on how its legislation and regulatory processes would have to be modified if the UK leaves the EU under a ‘no-deal’ scenario.
The regulator said it firmly believes “it is in the interests of both the EU and the UK to strike a deal”, but that “a responsible government should prepare for all potential outcomes”.
The overall approach in a no-deal scenario is for the MHRA to be a stand-alone medicines and medical devices regulator, taking any decisions and carrying out any functions which are currently taken or carried out at EU-level.
